Partnerships AstraZeneca: license to glucokinase activator IP in all indications (granted August 2024); Manoira (related party): joint development agreement evaluating the compounds in animal health
Indications
autoimmune disorders(Preclinical)
Status note Repurposed from a prior T2DM program (Phase 2 studies completed); company now repositioning in autoimmune disorders with preclinical work. No active clinical trial stated in excerpts.
AZD5658
Phase 1 · ActiveModality: small molecule (oral)
Target glucokinase
Partnerships AstraZeneca: licensed with AZD1656 (all indications)
Indications
not disclosed(Phase 1)
Status note Metabolite of AZD1656; completed single Phase 1 study in T2DM patients; no ongoing trial stated.
AZD5904
Phase 1 · ActiveModality: small molecule (oral)
Target myeloperoxidase (MPO)
Partnerships AstraZeneca: license for treatment, prevention and prophylaxis of idiopathic male infertility (granted August 2024)
Indications
idiopathic male infertility(Phase 1)
Status note Potent irreversible myeloperoxidase inhibitor; five Phase 1 studies completed. Business strategy is to generate preclinical data then seek third-party license deals; no active trial stated.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.